Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study
Alexis Trecourt,Naoual Bakrin,Olivier Glehen,Witold Gertych,Laurent Villeneuve,Sylvie Isaac,Nazim Benzerdjeb,Juliette Fontaine,Catherine Genestie,Peggy Dartigues,Agnès Leroux,François Quenet,Frederic Marchal,Cecile Odin,Lakhdar Khellaf,Magali Svrcek,Sixte Thierry,Marilyn Augros,Alhadeedi Omar,Mojgan Devouassoux-Shisheboran,Vahan Kepenekian,Julio Abba,Karine Abboud,Adeline Aimé,Koceila Amroun,Thierry André,Catherine Arvieux,Gerlinde Averous-Lang,Armelle Bardier,Houda Ben Rejeb,Jean-Marc Bereder,Philippe Bertheau,Frédéric Bibeau,Valérie Boige,Pierre-Emmanuel Bonnot,Olivier Bouché,Fatiha Bouhidel,Marie-Dominique Bouzard,Cécile Brigand,Chloé Broudin,Bertrand Celerier,Cécilia Ceribelli,Aurélie Charissoux,Anne Chevallier,Elise Clément,Julien Coget,Thomas Courvoisier-Clément,Marie Dazza,Cécile de Chaisemartin,Frédéric Di Fiore,Frédéric Dumont,Sylvaine Durand-Fontanier,Clarisse Eveno,Anne-Cécile Ezanno,Olivier Facy,Gwenaël Ferron,Johann Gagnière,Alexandre Galan,Maximiliano Gelli,Laurent Ghouti,Laurence Gladieff,Diane Goere,Jean-Marc Guilloit,Frédéric Guyon,Bruno Heyd,Marie-Françoise Heymann,Martin Hübner,Claire Illac-Vauquelin,Rachid Kaci,Amaniel Kefleysus,Reza Kianmanesh,Marie-Hélène Laverrière,Valérie Lebrun-Ly,Jérémie H. Lefevre,Bernard Lelong,Anne-Isabelle Lemaistre,Brice Malgras,Pascale Mariani,Antoine Mariani,Pierre Meeus,Eliane Mery,Fabrice Narducci,Stéphanie Nougaret,David Orry,Pablo Ortega-Deballon,Brice Paquette,Julien Péron,Patrice Peyrat,Denis Pezet,Nicolas Pirro,Marc Pocard,Flora Poizat,Judith Raimbourg,Patrick Rat,Pauline Ries,Pascal Rousset,Pierre-Yves Sage,Hélène Senellart,Olivia Sgarbura,Cristina Smolenschi,Isabelle Sourrouille,Abdelkader Taibi,Williams Tessier,Emilie Thibaudeau,Yann Touchefeu,Bertrand Trilling,Jean-Jacques Tuech,Séverine Valmary-Degano,Sharmini Varatharajah,Véronique Verriele-Beurrier,Guillaume Vogin,Romuald Wernert,Benoit You,
DOI: https://doi.org/10.1245/s10434-023-14850-0
IF: 4.339
2024-02-10
Annals of Surgical Oncology
Abstract:Abstract Background Ovarian pseudomyxoma peritonei (OPMP) are rare, without well-defined therapeutic guidelines. We aimed to evaluate cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat OPMP. Methods Patients from the French National Network for Rare Peritoneal Tumors (RENAPE) database with proven OPMP treated by CRS/HIPEC and with histologically normal appendix and digestive endoscopy were retrospectively included. Clinical and follow-up data were collected. Histopathological and immunohistochemical features were reviewed. Results Fifteen patients with a median age of 56 years were included. The median Peritoneal Cancer Index was 16. Following CRS, the completeness of cytoreduction (CC) score was CC-0 for 9/15 (60%) patients, CC-1 for 5/15 (33.3%) patients, and CC-2 for 1/15 (6.7%) patients. The median tumor size was 22.5 cm. After pathological review and immunohistochemical studies, tumors were classified as Group 1 (mucinous ovarian epithelial neoplasms) in 3/15 (20%) patients; Group 2 (mucinous neoplasm in ovarian teratoma) in 4/15 (26.7%) patients; Group 3 (mucinous neoplasm probably arising in ovarian teratoma) in 5/15 (33.3%) patients; and Group 4 (non-specific group) in 3/15 (20%) patients. Peritoneal lesions were OPMP pM1a/acellular, pM1b/grade 1 (hypocellular) and pM1b/grade 3 (signet-ring cells) in 13/15 (86.7%), 1/15 (6.7%) and 1/15 (6.7%) patients, respectively. Disease-free survival analysis showed a difference ( p = 0.0463) between OPMP with teratoma/likely-teratoma origin (groups 2 and 3; 100% at 1, 5, and 10 years), and other groups (groups 1 and 4; 100%, 66.6%, and 50% at 1, 5, and 10 years, respectively). Conclusion These results suggested that a primary therapeutic strategy using complete CRS/HIPEC for patients with OPMP led to favorable long-term outcomes.
oncology,surgery